In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.